CN1688547A - 作为抗肿瘤剂的a－′7－卤代－2－喹(喔)啉氧基苯氧基－丙酸衍生物 - Google Patents

作为抗肿瘤剂的a－′7－卤代－2－喹(喔)啉氧基苯氧基－丙酸衍生物 Download PDF

Info

Publication number
CN1688547A
CN1688547A CNA038158809A CN03815880A CN1688547A CN 1688547 A CN1688547 A CN 1688547A CN A038158809 A CNA038158809 A CN A038158809A CN 03815880 A CN03815880 A CN 03815880A CN 1688547 A CN1688547 A CN 1688547A
Authority
CN
China
Prior art keywords
compound
benzodiazepinyl
day
treatment
injection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA038158809A
Other languages
English (en)
Chinese (zh)
Inventor
杰罗姆P·霍维茨
托马斯·H·科贝特
埃德华都·帕洛敏诺
利萨·波林
斯图尔特·T·黑兹尔丁
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wayne State University
Original Assignee
Wayne State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wayne State University filed Critical Wayne State University
Publication of CN1688547A publication Critical patent/CN1688547A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
CNA038158809A 2002-07-03 2003-07-03 作为抗肿瘤剂的a－′7－卤代－2－喹(喔)啉氧基苯氧基－丙酸衍生物 Pending CN1688547A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39385802P 2002-07-03 2002-07-03
US60/393,858 2002-07-03

Publications (1)

Publication Number Publication Date
CN1688547A true CN1688547A (zh) 2005-10-26

Family

ID=30115656

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA038158809A Pending CN1688547A (zh) 2002-07-03 2003-07-03 作为抗肿瘤剂的a－′7－卤代－2－喹(喔)啉氧基苯氧基－丙酸衍生物

Country Status (18)

Country Link
US (3) US7109341B2 (enExample)
EP (1) EP1539699A1 (enExample)
JP (1) JP2005532397A (enExample)
CN (1) CN1688547A (enExample)
AU (2) AU2003249704B2 (enExample)
BR (1) BR0311491A (enExample)
CA (1) CA2491612C (enExample)
EA (1) EA009679B1 (enExample)
GE (1) GEP20074058B (enExample)
IL (1) IL164555A0 (enExample)
MX (1) MXPA05000233A (enExample)
NO (1) NO20050573L (enExample)
NZ (1) NZ535887A (enExample)
PL (1) PL373624A1 (enExample)
SG (1) SG145570A1 (enExample)
UA (1) UA79293C2 (enExample)
WO (2) WO2004005260A1 (enExample)
ZA (1) ZA200408191B (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103127112A (zh) * 2013-02-27 2013-06-05 江苏先声药物研究有限公司 一类喹啉酮衍生物在肿瘤治疗中的应用
CN105085480A (zh) * 2014-05-16 2015-11-25 湖南大学 2-[4-（喹喔啉-2-氧基）苯氧基]脂肪酰吡啶胺的医药用途
CN105085506A (zh) * 2014-05-16 2015-11-25 湖南大学 2-[4-（苯并噁唑-2-氧基）苯氧基]脂肪酰吡啶胺的医药用途
CN110698418A (zh) * 2019-09-11 2020-01-17 广西师范大学 一种3-芳胺基喹喔啉-2-甲酰胺类衍生物及其制备方法和应用

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA75691C2 (en) * 2001-07-31 2006-05-15 Univ Wayne State Quinoline derivatives, use thereof as antitumor drugs, composition based thereon and therapeutical method for treatment of cancer
UA79293C2 (en) * 2002-07-03 2007-06-11 Univ Wayne State 4-(7'-halo-2-quino (xa-) linyloxy)phenoxy propionic acid derivatives as antineoplastic agents
US20040106662A1 (en) * 2002-08-24 2004-06-03 Herbert Irschik Use of the disorazoles and their derivatives for the treatment of benign and malignant oncoses
CN100427482C (zh) * 2005-08-01 2008-10-22 复旦大学 N,n-二甲胺酰基-2,3-二呋喃基-6-氨基喹噁啉,其制备方法与应用
US20070054938A1 (en) * 2005-09-07 2007-03-08 Horwitz Jerome P Antitumor agents
US8183379B2 (en) * 2005-09-07 2012-05-22 Wayne State University Antitumor agents
US7470788B2 (en) * 2005-09-07 2008-12-30 Wayne State University Antitumor agents
EP1897542A1 (en) * 2006-09-07 2008-03-12 Sanofi-Aventis Aqueous formulation comprising an antitumor agent
US9096546B2 (en) * 2007-05-10 2015-08-04 Albany Molecular Research, Inc. Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
US9096544B2 (en) 2009-12-23 2015-08-04 Wayne State University Therapeutic compounds
CN107827828B (zh) * 2017-11-21 2021-03-30 南京华漫新材料科技有限公司 含苯酰肼骨架的喹喔啉衍生物及其制备方法和在制备抗肿瘤药物中的应用
TWI826034B (zh) * 2022-10-07 2023-12-11 宏碁股份有限公司 影像過曝改善方法及電子裝置

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54112628A (en) 1978-02-23 1979-09-03 Canon Inc Electromagnetic driving device
JPS6033389B2 (ja) * 1979-02-22 1985-08-02 日産化学工業株式会社 複素環エ−テル系フェノシキ脂肪酸誘導体、その製造法および該誘導体を含有する除草剤
US5364831A (en) * 1980-08-06 1994-11-15 Nissan Chemical Industries Ltd. Quinoxaline derivatives and herbicidal composition
US6197728B1 (en) * 1980-08-06 2001-03-06 Nissan Chemical Industries Ltd. Quinoxaline derivatives and herbicidal composition
US4760066A (en) * 1982-09-21 1988-07-26 Wayne State University Method for treating human tumor cell metastasis
US4559157A (en) * 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) * 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4710507A (en) * 1983-12-22 1987-12-01 Pfizer Inc. Quinolone inotropic agents
US5250690A (en) * 1985-05-02 1993-10-05 Dowelanco Haloalkoxy anilide derivatives of 2-4(-heterocyclic oxyphenoxy)alkanoic or alkenoic acids and their use as herbicides
JPS62190172A (ja) * 1986-02-14 1987-08-20 Teijin Ltd フエノキシ脂肪族カルボン酸誘導体および除草剤
US4820508A (en) * 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) * 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) * 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
WO1994013647A1 (en) * 1992-12-15 1994-06-23 The Du Pont Merck Pharmaceutical Company (2-quinoxalinyloxy)phenoxypropanoic acids and related derivatives as anticancer agents
US6680311B1 (en) * 1996-08-30 2004-01-20 Eli Lilly And Company Cryptophycin compounds
AU4233997A (en) * 1996-08-30 1998-03-19 Eli Lilly And Company Process for preparing pharmaceutical compounds
CA2264245A1 (en) * 1996-09-06 1998-03-12 Eli Lilly And Company Process to prepare pharmaceutical compounds
US6160006A (en) * 1996-10-18 2000-12-12 Wayne State University 6',7'-dihydroxybergamottin, a cytochrome P450 inhibitor in grapefruit
US6352991B1 (en) * 1997-01-08 2002-03-05 Wayne State University 2-hydroxymethylcyclopropylidenemethylpurines and -pyrimidines as antiviral agents
US6238644B1 (en) * 1997-09-03 2001-05-29 Wayne State University Method for treating and/or imaging breast cancer using radioactive iodide
US6586461B1 (en) * 1998-06-16 2003-07-01 Wayne State University Prenyl transferase inhibitors
US6103913A (en) * 1998-10-16 2000-08-15 Eli Lilly And Company Process for preparing enollactone derivatives
DE60114022T2 (de) * 2000-05-30 2006-07-13 Board Of Governors Of Wayne State University, Detroit Matrix metalloproteinase-inhibitoren
US6747021B2 (en) * 2000-10-02 2004-06-08 Eli Lilly And Company Cryptophycin compound
UA75691C2 (en) * 2001-07-31 2006-05-15 Univ Wayne State Quinoline derivatives, use thereof as antitumor drugs, composition based thereon and therapeutical method for treatment of cancer
UA79293C2 (en) * 2002-07-03 2007-06-11 Univ Wayne State 4-(7'-halo-2-quino (xa-) linyloxy)phenoxy propionic acid derivatives as antineoplastic agents

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103127112A (zh) * 2013-02-27 2013-06-05 江苏先声药物研究有限公司 一类喹啉酮衍生物在肿瘤治疗中的应用
CN105085480A (zh) * 2014-05-16 2015-11-25 湖南大学 2-[4-（喹喔啉-2-氧基）苯氧基]脂肪酰吡啶胺的医药用途
CN105085506A (zh) * 2014-05-16 2015-11-25 湖南大学 2-[4-（苯并噁唑-2-氧基）苯氧基]脂肪酰吡啶胺的医药用途
CN105085480B (zh) * 2014-05-16 2017-12-29 湖南大学 2‑[4‑（喹喔啉‑2‑氧基）苯氧基]脂肪酰吡啶胺的医药用途
CN105085506B (zh) * 2014-05-16 2018-01-19 湖南大学 2‑[4‑(苯并噁唑‑2‑氧基)苯氧基]脂肪酰吡啶胺的医药用途
CN110698418A (zh) * 2019-09-11 2020-01-17 广西师范大学 一种3-芳胺基喹喔啉-2-甲酰胺类衍生物及其制备方法和应用
CN110698418B (zh) * 2019-09-11 2022-07-01 广西师范大学 一种3-芳胺基喹喔啉-2-甲酰胺类衍生物及其制备方法和应用

Also Published As

Publication number Publication date
GEP20074058B (en) 2007-03-12
PL373624A1 (en) 2005-09-05
US7585863B2 (en) 2009-09-08
ZA200408191B (en) 2006-07-26
SG145570A1 (en) 2008-09-29
WO2004005260A1 (en) 2004-01-15
MXPA05000233A (es) 2005-04-11
UA79293C2 (en) 2007-06-11
CA2491612A1 (en) 2004-01-15
US7728007B2 (en) 2010-06-01
US7109341B2 (en) 2006-09-19
WO2004004651A2 (en) 2004-01-15
EP1539699A1 (en) 2005-06-15
BR0311491A (pt) 2005-04-26
US20090076073A1 (en) 2009-03-19
US20060293333A1 (en) 2006-12-28
CA2491612C (en) 2012-01-03
NO20050573L (no) 2005-02-02
JP2005532397A (ja) 2005-10-27
AU2003249704A1 (en) 2004-01-23
US20040132618A1 (en) 2004-07-08
AU2003249704B2 (en) 2010-05-20
EA009679B1 (ru) 2008-02-28
NZ535887A (en) 2006-11-30
AU2003249722A1 (en) 2004-01-23
IL164555A0 (en) 2005-12-18
EA200500095A1 (ru) 2005-06-30

Similar Documents

Publication Publication Date Title
CN1688547A (zh) 作为抗肿瘤剂的a－′7－卤代－2－喹(喔)啉氧基苯氧基－丙酸衍生物
CN1027068C (zh) α-取代的4-(喹啉-2-基-甲氧基)苯乙酸和酯的制备方法
CN1308311C (zh) 新型吡啶－和喹啉－衍生物
CN1158264C (zh) 用于治疗中枢神经系统疾病的代谢性谷氨酸受体拮抗剂
CN1207730A (zh) 喹啉衍生物
HK1048635A1 (zh) 代谢移变的谷氨酸盐受体拮抗剂和它们治疗中枢神经系统疾病的用途
CN1130345C (zh) 氨基喹啉衍生物
CN1104422C (zh) 用作α－2肾上腺素能受体兴奋剂的胍基杂环化合物
CN1639119A (zh) 取代的2－氨基－环烷烃甲酰胺和它们作为半胱氨酸蛋白酶抑制剂的用途
CN1133042A (zh) 吲哚衍生物
CN1135754A (zh) 治疗药剂
CN1224624C (zh) 1,8－二氮杂萘－2(1h)－酮衍生物
CN1956966A (zh) 喹唑啉衍生物及其治疗用途
CN1238771A (zh) 用作α－2肾上腺素能受体兴奋剂的2－咪唑啉基氨基吲哚化合物
CN1244577C (zh) 4－苯基－1－哌嗪基、－哌啶基和－四氢吡啶基衍生物
CN1067892A (zh) 新的吡咯并[2，3-b]吡啶衍生物的制备方法
CN1258276A (zh) 细胞增生抑制剂氰基胍
CN1205704A (zh) 2,7－取代的八氢－吡咯并[1,2－a]吡嗪衍生物
CN1807413A (zh) 咔唑磺酰胺衍生物及其制备方法
CN1642911A (zh) 作为单胺氧化酶b的抑制剂的邻苯二甲酰亚氨基衍生物
CN1145617A (zh) 吲哚衍生物及含它们的药物
CN1372556A (zh) 抑制血管生成的杂环化合物
CN1190423C (zh) 杂环衍生物和药物
CN1871013A (zh) 作为mao－b抑制剂的苯并氮杂䓬衍生物
CN1023479C (zh) 乙二胺的单酰胺衍生物的制备方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1081961

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20051026

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1081961

Country of ref document: HK